DelveInsight’s, “Cystic Fibrosis Pipeline Insight 2024” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in the Cystic Fibrosis pipeline landscape. It covers the Cystic Fibrosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Cystic Fibrosis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Cystic Fibrosis Pipeline Report

• DelveInsight’s Cystic Fibrosis pipeline report depicts a robust space with 75+ companies working to develop 80+ pipeline therapies for Cystic Fibrosis treatment.
• The leading companies working in the Cystic Fibrosis Market include Krystal Biotech, Vertex Pharmaceuticals, Translate Bio, Novartis, Algi Pharma, Verona Pharma, Atlantic Healthcare, Calithera Biosciences, Horizon Therapeutics, Santhera Pharmaceuticals, Reveragen Biopharma, Spli Sense, GlaxoSmithKline, EmphyCorp, Abbvie, Galapagos NV, Vertex Pharmaceuticals, PathBio Analytics, AstraZeneca, AxentisPharma AG, and others.
• Promising Cystic Fibrosis Pipeline Therapies in the various stages of development include Ciprofloxacin (Cipro Inhale, BAYQ3939), P-1037, Hypertonic Saline, VX-371 + HS, MP-376 (Levofloxacin solution for Inhalation), and others.
• May 2024:- Vertex Pharmceuticals Incorporated- A Phase 3b Open-label Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor Combination Therapy in Cystic Fibrosis Subjects Ages 6 Years and Older Who Are Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF).

 

Request a sample and discover the recent advances in Cystic Fibrosis Treatment Drugs @ Cystic Fibrosis Pipeline Report

 

In the Cystic Fibrosis pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cystic Fibrosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Cystic Fibrosis Overview

Cystic fibrosis is a progressive, genetic disease that causes long-lasting lung infections and limits the ability to breathe over time. More than 30,000 children and adults in the United States have CF (70,000 worldwide) and CF affects people of every racial and ethnic group.

 

Find out more about Cystic Fibrosis Therapeutics Assessment @ Cystic Fibrosis Preclinical and Discovery Stage Products

 

Cystic Fibrosis Emerging Drugs Profile

• OligoG: Algi Pharma
• Ensifentrine: Verona Pharma
• MRT5005: Translate Bio
• CB280: Calithera Biosciences
• KB407 : Krystal Biotech
• SPL84231: SpliSense

 

Cystic Fibrosis Pipeline Therapeutics Assessment

There are approx. 75+ key companies which are developing the Cystic Fibrosis therapies. The Cystic Fibrosis companies which have their Cystic Fibrosis drug candidates in the most advanced stage, i.e. phase II include, Algi Pharma.

 

Learn more about the emerging Cystic Fibrosis Pipeline Therapies @ Cystic Fibrosis Clinical Trials Assessment

 

Scope of the Cystic Fibrosis Pipeline Report

• Coverage- Global
• Cystic Fibrosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Cystic Fibrosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Cystic Fibrosis Companies- Krystal Biotech, Vertex Pharmaceuticals, Translate Bio, Novartis, Algi Pharma, Verona Pharma, Atlantic Healthcare, Calithera Biosciences, Horizon Therapeutics, Santhera Pharmaceuticals, Reveragen Biopharma, Spli Sense, GlaxosmithKline, EmphyCorp, Abbvie, Galapagos NV, Vertex Pharmaceuticals, PathBio Analytics, AstraZeneca, AxentisPharma AG, and others.
• Cystic Fibrosis Pipeline Therapies- Ciprofloxacin (Cipro Inhale, BAYQ3939), P-1037, Hypertonic Saline, VX-371 + HS, MP-376 (Levofloxacin solution for Inhalation), and others.

 

Dive deep into rich insights for new drugs for Cystic Fibrosis Treatment, Visit @ Cystic Fibrosis Market Drivers and Barriers, and Future Perspective

 

Table of Content

1. Introduction
2. Executive Summary
3. Cystic Fibrosis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Cystic Fibrosis – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug name: Company Name
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. OligoG : Algi pharma
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. CB280:Calithera Biosciences
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. SPL84231: Spli Sense
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Cystic Fibrosis Key Companies
21. Cystic Fibrosis Key Products
22. Cystic Fibrosis Unmet Needs
23. Cystic Fibrosis Market Drivers and Barriers
24. Cystic Fibrosis Future Perspectives and Conclusion
25. Cystic Fibrosis Analyst Views
26. Cystic Fibrosis Companies
27. Appendix

 

For further information on the Cystic Fibrosis Pipeline therapeutics, reach out to Cystic Fibrosis Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/